HHT diagnosis by Mid-infrared spectroscopy and artificial neural network analysis by Andreas Lux et al.
Lux et al. Orphanet Journal of Rare Diseases 2013, 8:94
http://www.ojrd.com/content/8/1/94RESEARCH Open AccessHHT diagnosis by Mid-infrared spectroscopy
and artificial neural network analysis
Andreas Lux1*, Ralf Müller2, Mark Tulk2, Carla Olivieri3, Roberto Zarrabeita4, Theresia Salonikios5
and Bernhard Wirnitzer5Abstract
Background: The vascular disorder Hereditary Hemorrhagic Telangiectasia (HHT) is in general an inherited disease
caused by mutations in the TGF-β/BMP receptors endoglin or ALK1 or in rare cases by mutations of the TGF-β
signal transducer protein Smad4 leading to the combined syndrome of juvenile polyposis and HHT. HHT is
characterized by several clinical symptoms like spontaneous and recurrent epistaxis, multiple telangiectases at sites
like lips, oral cavity, fingers, nose, and visceral lesions like gastrointestinal telangiectasia, pulmonary, hepatic, cerebral
or spinal arteriovenous malformations. The disease shows an inter- and intra-family variability in penetrance as well
as symptoms from mild to life threatening. Penetrance is also depending on age. Diagnosis of the disease is based
on the presence of some of the listed symptoms or by genetic testing. HHT diagnosis is laborious, time consuming,
costly and sometimes uncertain. Not all typical symptoms may be present, especially at a younger age, and genetic
testing does not always identify the disease causing mutation.
Methods: Infrared (IR) spectroscopy was investigated as a potential alternative to the current diagnostic methods.
IR-spectra were obtained by Fourier-transform Mid-IR spectroscopy from blood plasma from HHT patients and a
healthy control group. Spectral data were mathematically processed and subsequently classified and analysed by
artificial neural network (ANN) analyses and by visual analysis of scatter plots of the dominant principal
components.
Results: The analyses showed that for HHT a disease specific IR-spectrum exists that is significantly different from
the control group. Furthermore, at the current stage with the here used methods, HHT can be diagnosed by
Mid-IR-spectroscopy in combination with ANN analysis with a sensitivity and specificity of at least 95%. Visual
analysis of PCA scatter plots revealed an inter class variation of the HHT group.
Conclusion: IR-spectroscopy in combination with ANN analysis can be considered to be a serious alternative
diagnostic method compared to clinical and genetically based methods. Blood plasma is an ideal candidate for
diagnostic purposes, it is inexpensive, easy to isolate and only minimal amounts are required. In addition, IR-
spectroscopy measurement times are fast, less than one minute, and diagnosis is not based on interpretation of
may be uncertain clinical data. And last but not least, the method is inexpensive.
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The vascular disorder Hereditary Haemorrhagic Telangi-
ectasia (HHT) affects 1 in 5.000 to 8.000 people and is
in general inherited in an autosomal-dominant way [1,2],
but de novo affections are also reported. The disease is
thought to be present in all races and parts of the world
[3]. HHT is commonly caused by mutations in either the
endoglin [4] or ALK1 [5] gene and in rare cases in
SMAD4. SMAD4 mutations lead to the combined syn-
drome of juvenile polyposis (JP) and HHT (JP-HHT)
[6,7]. All three genes code for proteins involved in the
TGF-beta/BMP pathways. By linkage analysis, two add-
itional regions on chromosome 5q31.3-5q32 [8] and
7p14 [9], respectively, were identified that might harbour
HHT related genes, which are so far not identified and
will only count for a small number of HHT cases.
HHT is a vascular disorder and the research of the
last 20 years has shown that the TGF-ß/BMP receptors
endoglin and ALK1 and Smad4, as an intracellular sig-
nal transducer protein, are involved in the different an-
giogenic processes. On the micro anatomic level HHT
is characterised by a distorted and convoluted capillary
bed with shunts between the arterial and venous system.
The mutations in the different HHT genes can lead to
different phenotypes and clinical symptoms, which are
a) spontaneous and recurrent epistaxis, b) multiple tel-
angiectases at characteristic sites like lips, oral cavity,
fingers and nose, and c) visceral lesions like gastrointes-
tinal telangiectasia, pulmonary, hepatic, cerebral or spinal
arteriovenous malformations [3]. The disease shows an
inter- and intra-family variability in penetrance as well as
symptoms from mild to life threatening and penetrance is
also depending on age. Not all typical symptoms may be
present, especially at a younger age, when a suspected
HHT patient is presented to a physician. For example, sev-
eral studies have reported an average age of 12 years for
the onset for epistaxis, with nearly 100% affected by the
age of 40 (reviewed in [2,3,10]. Furthermore, most patients
report the appearance of telangiectasia of the mouth, face
or hands 5 to 30 years after the onset of nose bleeds, most
commonly during the third decade. In general, most pa-
tients show a full penetrance of the disease around the age
of 40. However, in rarer cases the disease can start at an
older age or very rarely the symptoms are that mild that
these patients might be missed to have HHT. In the year
2000, consensus clinical diagnostic criteria, known as the
Curacao Criteria, were established for the diagnosis of
HHT [11]. These criteria include, aside from the clinical
symptoms, also as a single independent criteria if someone
has first degree relatives with HHT. By these guidelines,
HHT is considered to be definite if three or more criteria
are present, possible or suspected diagnosis if two criteria
are present, and unlikely if none or only one criterion is
present. Nevertheless, the penetrance of symptoms varies,also in regard of age, and therefore HHT patients might
not be diagnosed with HHT. A recent questionnaire based
study reports a long diagnostic delay in patients with
HHT [12]. In this study the average clinical onset of dis-
ease occurred at an age of about 14 years. Whereas the
age of first referral and the first definite diagnosis were at
an age around 29 and 40 years, respectively. When a per-
son is diagnosed, it is not unusual to identify multiple rela-
tives in the family who have not been labelled with HHT
but who have struggled for example with epistaxis, em-
bolic stroke, or GI bleeding.
Based on the different clinical symptoms, HHT diag-
nosis can be laborious, time consuming, costly and un-
certain. Aside of clinical diagnosis by different methods,
genetic testing for the disease genes endoglin, ALK1 or
Smad4 is a further but also costly option and the disease
causing mutation might not always be detected. There-
fore, it would be desirable to have a diagnostic tool at
hand that facilitates diagnosis, especially for those physi-
cians and general practitioners that have no experience
with the disease.
A diagnostic tool that will lead to an earlier, faster,
cheaper and easier diagnosis might be the infrared (IR)-
spectroscopy. In the past years, Near- and Mid-IR spec-
troscopy, which is well established for quality control in
the chemical industry and material sciences, has emerged
as a possible alternative diagnostic method for different
diseases and other purposes. IR-spectroscopy of body
fluids like blood plasma, serum or urine has been shown
to reveal disease-specific changes in spectral signatures,
for in example bovine spongiform encephalopathy [13],
diabetes mellitus [14], rheumatoid arthritis [15], β-
Thalassemia [16] or myocardial infarction and heart
failure [17]. Furthermore, IR-spectroscopy can also be
used for measuring the concentration of different clin-
ically relevant constituents of body fluids: albumin,
cholesterol, glucose, total protein, urea, tri-glycerides,
uric acid, phosphate, creatinine [18] or plasma haemo-
globin [19]. IR-spectroscopy is based on the detection
of molecular vibrations in different chemical groups of
i.e. proteins, lipids, nucleic acids. The idea behind using
IR-spectroscopy in diagnostic is that the disease leads to
an overall change in molecule and group composition
of the different molecules that is different from the
spectrum of non-affected people, resulting in a disease-
specific IR-fingerprint.
In this study, we used blood plasma in combination
with Fourier-transform Mid-infrared spectroscopy and
Artificial Neural Network (ANN) analyses in order to
test if for HHT a disease specific IR-fingerprint exists
and whether IR-spectroscopy from patient plasma might
be a feasible diagnostic alternative to the current prac-
tice or not. Blood plasma is an ideal candidate for diag-
nostic purposes because it is inexpensive and easy to
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can diagnose HHT by IR-spectroscopy and ANN ana-
lysis with a specificity and sensitivity of at least 95%.
Methods
Patient and control samples
For this study, EDTA blood samples of 2.5 ml were sent
to us either by the HHT patients or their attending phy-
sicians by regular postal mail. Transport time of samples
was between one and three days but in general only one
day. After blood sample arrival, 0,5 ml blood was stored
away at −80°C for those patients with unknown genetic
status, for possible future mutation analysis. From the
remaining 2 ml, plasma was collected by centrifugation
for 10 min at 4°C with at least 13.000 rcf. Plasma was
stored at −20°C until use. The majority of patient samples
were from German patients. However, a small number of
19 Italian patients and 4 Spanish patients plus one nega-
tive control were also included. The Italian samples were
sent as plasma on dry ice, whereas the Spanish samples
were sent as EDTA blood. Blood plasma from blood
donors from the blood donating centre in Mannheim
served as the healthy control group. These plasma samples
were processed by the centre. The study was approved by
the medical ethic committee II of the Medical Faculty
Mannheim, University of Heidelberg. In order to decide
upon the disease status of the patients they had to fill out
a questionnaire regarding their symptoms, genetic status
and whether first degree relatives are affected by HHT.
Based on this information, only the spectra of patients that
fulfilled three criteria for HHT were used for the spectral
pattern analysis. Unfortunately, not for all patients the
questionnaire was returned and their samples were ex-
cluded from this study.
FT-IR spectroscopy
1 μl blood plasma was diluted in 3 μl HPLC-water and of
this three times 1 μl were spotted randomly onto a 384
well Si-sample carrier at three different places. The plate
was then dried overnight in a descicator. Next, the plate
was placed into an HTS-XT micro plate reader and the
spectra were recorded with a Tensor 37 FT-IR Spec-
trometer (Bruker Optics GmbH, Ettlingen, Germany).
Mid-infrared spectra were measured by diffuse reflectance
and were recorded in the spectral range between 4.000
and 400 cm-1.
Data analysis of IR-spectra with Pattern Expert
Preliminary data processing was performed with the
Optics User Software (OPUS) from Bruker Optics. In
brief, the obtained spectra were preprocessed by vector
normalization and the first and second derivative of the
original spectra were formed using the Savitzky-Golay
algorithm with nine smoothing points. Subsequently,the data was loaded into the Artificial Neural Network
(ANN) software Pattern Expert Airspect (Pattern Ex-
pert, Borsdorf, Germany). For spectra and data analysis
and configuration the programs standard settings for
feature computation (ROI, regions of interest), feature
selection (all features) and classifier construction (ANN
linear) were used.
The samples were separated into two groups, healthy
and HHT positive, based on our information from the
answered questionnaires and the known mutations. The
program then compares the IR bands of all healthy sam-
ples and all diseased samples to establish an average IR
pattern for each respective group. Next, the average of
each group is compared against one another to deter-
mine ‘regions of interest’ (ROIs), that is, regions with
significant differences in the bands, which are used to
decide whether a specific IR band belongs to the healthy
or HHT positive group.
The next step is the supervised classification using an
ANN. This step represents the learning phase of the au-
tomated neural network leading to a recognition module
by which the spectra are classified into an HHT group
and a healthy non-HHT group, summarized in a Classifi-
cation Table (also denoted as confusion matrix). This
table contains the results of a final stratified cross valid-
ation using the best recognition module found. Its rows
correspond to the target class, i.e. the classes the spectra
actually belong to, while the columns correspond to the
ANN output class, i.e. those classes they have been
assigned to by the recognition module. The diagonal ele-
ments of the table correspond to correctly assigned sam-
ples while the off diagonal elements correspond to false
classification. Once the classification step is done the
program performs a so called external cross validation.
For every set of parameters used the program re-
evaluates to which group each IR signal belongs to. After
trying all combinations and discovering which set yields
the most accurate predictions, an external cross valid-
ation is performed. This procedure involves randomly
selecting 10% of the samples being used from each group
and treating them as if they are unknown. They are then
compared to the average signal of the remaining 90% of
each group and assigned to the group their signal matches
more exactly. This is repeated 10 times for each signal,
using different ROIs each time. The ROIs used for this cal-
culation come from the previously decided upon range.
The multiple repetitions of each comparison lead to the
program deciding upon a confidence level for each of its
decisions, ranging from 50-100%. After the program has
designated each of the selected spectra to a group it selects
another 10% of the total samples and begins to evaluate
them in the same way it studied the previous group. This
process repeats itself until all 100% of samples being con-
sidered have been measured. After the cross validation is
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check the accuracy of each prediction and the programs
confidence level in its decision
Sequencing
DNA from blood samples (patients) 306 (ENG exon 11
mutation), 334 and the mother (ALK1 exon 9 mutation)
of patient 334 were isolated with a DNA extraction Kit
(Q-bios GmbH). Extracted DNA was used in a PCR for
exon amplification. Exons were amplified in a standard
PCR with a HotStart Taq Polymerase (Q-bios). Amplified
exons were gel purified (Gel Purification Kit, Q-bios) and
the purified exon DNA was used in a sequencing reaction
with the Big Dye Terminator v1.1 Kit according to the
manufacturer's instructions. Sequences were run on an
ABI 310 Prism Genetic Analyzer (Applied Biosystems).
For exon amplification the following primers were used:
ENG exon 11 forward, gctaccacgagctcggccgatatttgaag
gcagcag; ENG exon 11 reverse, 5'-gtcgccgtcgctctaggca
aaccacagacctggaag-3'; ALK1 exon 9 forward, 5'-gctaccacga
gctcggggcctccttagagtcccaag-3'; ALK1 exon 9 reverse, 5'-
gctaccacgagctcggcagaaatcccagccgtgag-3'; forward sequen-
cing primer 5'-gctaccacgagctcgg-3'; reverse sequencing
primer, 5'-gctaccacgagctcgg-3'. The underlined sequences
in the exon primers are not exon-specific but are specific
for the sequencing primers.
Results
Most of the here used samples were analysed in two in-
dependent studies by two different investigators with
similar results. In pre-emption of the results, both inves-
tigations showed that there is an HHT-specific IR-
fingerprint. Here we present the results of the second
study, which included more samples. In this study, 192
blood plasma samples from 191 HHT patients were
analysed. The majority of samples, 169, were collected
from 168 German patients with the help of the German
patient group Morbus Osler Selbsthilfe e.V. Smaller
sample numbers were provided from Italy (19) and Spain
(4). The blood plasma from 191 blood donors served as
the non-HHT control group. Plasma samples from 7
HHT relatives having no HHT (samples 162, 214, 214a,
306, 320, 332, 334, 354, 359, one sample from an
Angioma serpiginosum patient (sample 310) and one
non-HHT sample (sample 358) from Spain were added
to the control group. In total, 202 samples. The average
age of the HHT group was 54.1 years (+/− 12,6 years).
The average age of the control group was 43.2 years
(+/− 13,6 years). For two non-HHT persons from the
HHT relative group we received two samples at different
times, samples 214(214a)/354, and samples 306/359.
Sample 214 and 214a represent the same blood probe
but plasma from this probe was measured twice at dif-
ferent times. From the non-HHT group two people,corresponding to samples 334 and 306/359, were investi-
gated for a mutation in ALK1 or endoglin, respectively.
Sequencing confirmed that they do not carry the family-
specific HHT mutation.
Mutation status of analysed patients
For our first evaluation, in order to see whether an
HHT-specific IR-spectrum exists or not, we only used
samples from patients with a confirmed mutation in
endoglin or ALK1. This group consisted of 63 patients.
Seven more patient samples with a defined genetic status
for endoglin, ALK1 or SMAD4 were included in the sec-
ond analysis with a larger number of samples. In the
German patient group 16 patients have an endoglin muta-
tion, 29 an ALK1 mutation and two a SMAD4 mutation.
For the Italian and Spanish group 7 endoglin and 16
ALK1 mutations were reported. The mutations are listed
in Table 1. The majority of mutations are already known
and are listed in the HHT Mutation Database (http://
www.arup.utah.edu/database) hosted by the University of
Utah Department of Pathology and ARUP Laboratories.
However, 17 mutations were not found in the database
and might be new.
Analysis of spectra from genetically defined patients with
the Pattern Expert Airspect software
In order to evaluate whether HHT patients show a
disease-specific fingerprint in the Mid-IR spectrum or
not, we first tested our hypothesis with 63 genetically
confirmed endoglin and ALK1 HHT patients. This ana-
lysis clearly showed that the spectrum of HHT patients
is different from the control group of 191 blood donors.
For the evaluation of the spectra with an Artificial
Neural Network (ANN) the Pattern Expert Airspect soft-
ware was used. The spectra were analysed with the pro-
grams standard setting. For the analysis two spectral
regions from 3150–2750 cm-1 and 1.850 - 750 cm-1 were
selected. Therefore, excluding a possible water band at
3350 cm-1 and the CO2 band at 2200 cm
-1. Figure 1
shows the mean second derivative spectra for all patients
(red line) and all controls (green line).
By simple visual comparison a difference between the
two spectra can already be observed. The control group
waves show higher amplitude at different wave number po-
sitions than the HHT group but follow the same wave pat-
tern except for the region from 1750 cm-1 to 1600 cm-1.
After the learning phase, 190 blood donors of 191 were
correctly classified into the non-HHT group (Table 2). Of
the 63 patients, 60 were classified into the HHT group.
Next, the program performed the external cross validation,
which can be considered as the training and validation/test
phase in one step. Based on this, blood donor samples
84_Av and 11_Av were classified into the HHT group with
a very high and a very low confidence level (see Table 3),





Mutation Reported in ARUP data base /





74 German ALK1 Exon 9, c.1297C > T (p.P433S) HHT data base no information 54
105 Spanish ALK1 Exon 8, c.1205 G > A, p.G402D HHT data base no information 30
106 Spanish ALK1 Exon 8, c.1205 G > A, p.G402D HHT data base no information 64
165 German ENG (c.1712delG)/(p.Arg571fr) HHT data base E, T 40
166 German ENG, c.324-325InsT (Codon 109) HHT data base E, T, PAVM, HAVM, GI,
PH
66
169 German ALK1, p.Q292P (Exon 7) HHT data base E, T 69
178 German ALK1, c926-930del, GGCCATCAGGAAAA
(IVS5-8)
not reported E, T, PAVM, GI 69
182 German ALK1 (c.313 + 1_313 +
13delGTACGTCCAGCTG)(p.L106fsX129)
not reported E, T 64
183 German ALK1, c.905T > G, p. L302R HHT data base E, T, GI 67
184 German ALK1, c221delG, pR74fx47 not reported T, GI 80
199 German ENG, c.1015-1024delGCACCGATCC (Exon 8) not reported E, T, PAVM 61
201 German ALK1, c.186-190delCCCC (Exon 3) not reported E, T 81
202 German ALK1, c.570-573delCCCC (Exon 6) not reported E, T, HAVM, bladder 81
204 German ENG, c.1243C-T, p.Q415X HHT data base E, T, PAVM 66
208 German ALK1, c.806C-A, p.S269X not reported E, T 54
216 German ALK1, c.1207C > G, p.L403V not reported E, T, HAVM 60
223 German ENG, c.360G > A Intron 3 HHT data base E, T 69
228 German ALK1, c.881T > G, p.L294R not reported E, T, PAVM 39
232 German ALK1 gene deletion (one allele) not reported (E), T, PAVM 51
241 German ALK1, c.1130C > A, p.A377E, Exon 8 not reported E, T, GI 59
254 German ENG, c.1015-1024delGCACCGATCC (Exon 8) not reported E, T 56
258 German ALK1, c.1048G > A, p.G350S HHT data base E, T, CAVM, HAVM, GI 61
259 German ALK1, c.905T > G, p. L302R HHT data base E, T 67
264 German ALK1 (c.313 + 1_313 +
13delGTACGTCCAGCTG)(p.L106fsX129)
not reported no symptoms reported 36
272 German ENG, c.274-277delC (Exon 3) not reported E, T, PAVM, HAVM 69
279 German ALK1, c.998G > T, p.S333I (Exon 7) HHT data base E, T, HAVM 74
280 German ENG, c.1686 + 1G > A (Splice Mutation) not reported E, T, CAVM, PAVM 41
283 German ENG, c.324-325InsT, Codon 109 HHT data base E, T, PAVM 68
284 German ALK1, c.1120 C > T, p.R374W HHT data base no information 64
292 German SMAD4, c.1087T > C; p.C363R Smad4 data base E, T, PAVM, GI, JP 35
297 German ENG, c.1103T > C, p.M368T HHT data base E, T, PAVM 45
298 German ENG, c.1103T > C, p.M368T HHT data base E, T 67
299 German ENG exon 11, c.1432-33 delAGfs HHT data base E, T, PAVM, PH 71
301 German ALK1 Exon 3, c.200G > A, p.R67G HHT data base E, T 65
304 German ALK1, c.998G > T, p.S333I (Exon 7) HHT data base E, T, HAVM 49
316 German ENG, c.duplikation Exon2-4 HHT data base E, T, PAVM, GI 57
317 German ENG, c.360 + 5G > T (IVS3 + 5G > T) not reported E, T, PAVM, GI 68
324 German ENG, c.360C > A (Exon 3), p.Y120X HHT data base E, T 60
325 German SMAD4, c.1157G > A, p.G386D Smad4 data base E, T, PAVM, JP 39
326 German ALK1 gene deletion (one allele) not reported (E) 23
327 German ALK1, c.145-146InsG (GCC49GGCC) HHT data base E, T, GI 78
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Table 1 List of mutations of genetically confirmed HHT patients (Continued)
329 German ALK1 Exon 5, c.540-541insA HHT data base E, T 39
330 German ENG Intron 3, c.361-2A > G HHT data base E, T, PAVM, spinal
abscess, stroke
44
333 German ALK1, Exon8, c.1231G > A, p.R411Q HHT data base E, T 67
339 German ALK1, Exon 5, c.540-541insA HHT data base (E), T 39
342 German ALK1 Exon 5, c.540-541insA HHT data base E, T 42
347 German ALK1, Exon 7, c.788A > G, p.Asp263Gly not reported E, T, PH 37
353 German ALK1 (c.1120 C > T)(p.Arg374Trp) HHT data base E, T 45
356 Spanish ENG, exon 2, pF71fs HHT data base no information -
357 Spanish ALK1, exon 7, pH297fs not reported no information -
360 Italian ALK1, Exon 3, c.289_294 delCACAAC (p.
H97_N98del)
HHT data base no information 27
361 Italian ALK1, Exon 8, c.1112 G > A (p.G371D) not reported no information 66
362 Italian ENG , Exon 8, c.1097_1119 del23bp (p.
D365EfsX22
HHT data base no information 3
363 Italian ALK1, Exon 8, c.1231 C > T (p.R411W) HHT data base no information 25
364 Italian ALK1, Exon 7, c.824 dupGGCT (p.
L275LfsX118)
HHT data base no information 40
365 Italian ALK1, Exon 4, c.314-3 C > G (Splice Site) HHT data base no information 37
366 Italian ENG, Exon 3, c.360 + 1 G > A (Splice Site) HHT data base no information 65
367 Italian ALK1 , Exon 6, c.743_744 delCA (p.
T248SfsX142)
not reported no information 63
368 Italian ALK1, Exon 7, c.809_821
delCACGCAGCTGTGG (p.270SfsX27)
HHT data base no information 72
369 Italian ENG , Exon 8, c.1085_1086 insA (p.
T361fsX395)
not reported no information 68
370 Italian ALK1, Exon 7, c.853 dupC (p.L285PfsX107) not reported no information 66
371 Italian ALK1, Exon 10, c.1435 C > T (p.R479X) HHT data base no information 44
372 Italian ENG, Exon 3, c.360 + 1 G > A (Splice Site) HHT data base no information 77
373 Italian ENG, Exon 3, c.277 C > T (p.R93X) HHT data base no information 73
374 Italian ALK1, Exon 3, c.200 G > A, p.R67G HHT data base no information 48
375 Italian ENG, Exon6, c.816 + 5 G > C (Splice Site) HHT data base no information 38
376 Italian ALK1, Exon 8, c.1232 G > A (p.R411Q) HHT data base no information 49
377 Italian ALK1, Exon 8, c.1231 C > T (p.R411W) HHT data base no information 64
378 Italian ALK1, Exon 7, c.809_821
delCACGCAGCTGTGG (p.270SfsX27)
HHT data base no information 63
379 German ALK1, Exon 3, c.286A > G; p.N96D HHT data base T, PAVM 23
AVM arterio-venous malformation, E epistaxis every two weeks or more or daily episodes; (E), on average epistaxis once a month or less; T telangiectases (lips,
oral cavity, fingers and nose), CAVM cerebral AVM, HAVM hepatic AVM, PAVM pulmonary AVM, GI gastro intestinal telangiectases, PH pulmonary hypertension.
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miss-classified to belong to the “healthy” blood donor
group with high confidence levels for samples 333, 342,
371 and low confidence levels for samples 254 and 297
(see Table 3). There might be a high uncertainty regarding
a correct classification for samples with confidence levels
of around 50%, because these samples are close to the deci-
sion boundary with most likely a high standard deviation,
an output the program unfortunately does not show.For the evaluation, the ANN was set to analyse up to
300 spectral features spread over two spectral regions but
we do not know how many features the program really
used. Sometimes, one spectral region is less informative
than the other and thus, one spectral region may be
neglected for analysis. The spectral difference, which we
observed between 1750 cm-1 and 1600 cm-1, suggested
that the region 1.850 - 750 cm-1 is more informative and
therefore, sufficient for an ANN analysis and might lead
Figure 1 Second derivative spectra of healthy control and genetically confirmed HHT patients. Shown is the mean spectrum of all 191
control spectra in green and the mean spectrum of 63 patient spectra in red for spectral regions 3150–2750 cm-1 (A) and 1.850 - 750 cm-1 (B).
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case. After cross validation, only blood donor sample
84_Av was still classified into the HHT group with about
the same high confidence level as before. Again, five pa-
tient samples were classified to belong to the control
group. But it is interesting and important to note that this
time samples 254 and 371 were not in the false negativegroup anymore but were replaced by 199 (55% confi-
dence) and 327 (68% confidence). Furthermore, the confi-
dence levels for samples 297 and 342 increased to 72%
and 96%, respectively. These first data show that there is
an HHT disease specific IR-fingerprint and that both
analysed spectral regions contain HHT-specific important
features but with a higher weighting for features in region
Table 4 Classification of all HHT patients and the healthy








193 (95,5%) 9 (4,5%) 202
Positive (HHT
patients)
8 (4,2%) 184 (95,8%) 192
Sum 201 193 394
Classification is based on a recognition module established by the Pattern
Expert Airspect program after analysis of both spectral regions 3.150 - 2.750
cm-1 and 1.850 - 750 cm-1.
Table 2 Classification table for the genetically confirmed






Negative (blood donors) 190 (99,5%) 1 (0,5%) 191
Positive (genetically confirmed
HHT patients)
3 (4,8%) 60 (95,2%) 63
Sum 193 61 254
Classification is based on a recognition module established by the Pattern
Expert Airspect program after analysis of both spectral regions 3.150 – 2.750
cm-1 and 1.850 - 750 cm-1.
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http://www.ojrd.com/content/8/1/941.850 - 750 cm-1. Based on the results from the external
cross validation (Table 4) with this relatively small group
of patients we calculated a sensitivity of 92% [correct posi-
tive/(correct positive + false negative)] and a specificity of
99% [correct negative/(correct negative + false positive)].Analysis of spectra from all HHT patients with the Pattern
Expert Airspect software
The previous experiment and analysis has proven that
for HHT a disease-specific fingerprint in the Mid-IR
spectrum exists. This fingerprint was established with a
relatively small number of samples. Thus, in the next
step, we repeated our analyses with a larger number of
HHT patients, in total 191, including all genetically con-
firmed patients and those patients that fulfilled the
Curaçao criteria, represented by 192 plasma samples. For
one patient we had two samples collected at different
times. The control group consisted of plasma samples
from the blood donors as well as a group of non-HHT af-
fected HHT relatives, in total 201 samples.
Figure 2 shows the mean second derivative IR-
spectrum of the healthy control group (green line) and
the HHT group (red line). In Table 4 the classification
results are summarized. In Table 5 those samples are
shown that were possibly misclassified after the external
cross validation analysis. Samples are listed with theirTable 3 Confidence level of misclassified genetically
confirmed HHT patients after analysis of both
spectral regions
Non-HHT samples classified into
the HHT group (false positive)
HHT patient samples classified
into the control group (false
negative)
15_Av (52%) 254 (56%)




Confidence levels were calculated by the Pattern Expert Airspect program
after ANN and cross validation analysis with blood donor samples and
genetically confirmed HHT patient samples for spectral regions 3.150 - 2.750
cm-1 and 1.850 - 750 cm-1.confidence level. The classification results gave a specifi-
city and sensitivity of about 96% but based on the results
from the external cross validation (Table 5) we calcu-
lated after the analysis of this larger group a sensitivity
and specificity of 95%.
Like before, we repeated the evaluation by analysing
only the spectra for region 1.850 cm-1 – 750 cm-1.
Again, no major difference or improvement in sensitivity
and specificity of disease prediction was observed. The
group of false positives and negatives consisted mostly
of the same samples as before. The group of false posi-
tives were the same except for samples 3_Av and 95_Av,
which were assigned to the negative control group. The
group of false negatives again were sample 300 (96%),
330 (87%), 333 (100%), 348 (86,5%), 350 (93%) and 356
(100%), plus samples 352 (57%), 353 (53%) and 199
(50%) but this time without samples 287, 297, 324, 325.
The numbers in brackets represent the confidence level.
The classification of samples 199, 352 and 353 has to be
interpreted with caution because of the low confidence
level. Again, there is a high uncertainty regarding a cor-
rect classification for samples with confidence levels of
around 50% as explained before. These data suggest that
under the analysis parameters chosen here both spectral
ranges contain disease specific regions and therefore
should be included in the ANN analysis for an optimal
prediction.
Bhattacharyya coefficient based feature selection and
ANN analysis
This first analysis of the spectra by a commercial cus-
tomer friendly ANN analysis software package provided
already very good results. But we were concerned re-
garding some of the false positive and negative calls.
Especially in those cases where we knew that these pa-
tients are definitely HHT positive or HHT negative.
Therefore, we started to reanalyse the spectra in more
detail, which can also be considered to be the more
“classical” approach.
For this analysis, again the regions 3150 cm-1 - 2750 cm-1
and 1850 cm-1 - 750 cm-1 were selected from the pre-
processed spectra and both regions were normalized
Figure 2 Second derivative spectra of healthy control and all HHT patients. Shown is the mean spectrum of 202 control spectra in green
and the mean spectrum of 192 patient spectra in red for spectral regions 3150–2750 cm-1 (A) and 1.850 - 750 cm-1 (B).
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performed the feature selection. In order to identify those
wave numbers (features) that allow for the best differenti-
ation between patient and healthy control group (classes),
we used the Bhattacharyya coefficient. For each wave
number the Bhattacharyya coefficient was calculated. A
wave number was selected if Bhattacharyya coefficientwas greater than 5% of the greatest coefficient. By this
criterium 238 features distributed over both regions
were identified to be relevant in order to differentiate
between the non-HHT and HHT group. However, at
high wavenumbers, 3050 cm-1 - 2750 cm-1, the relevant
wavenumber regions are sparse and have only low
Bhattacharyya coefficients between 5% - 9%. Thus, Figure 3
Table 5 Confidence level of misclassified HHT patients
after analysis of both spectral regions
Non-HHT samples classified into
the HHT group (false positive)
HHT patient samples classified
into the control group
(false negative)
3_Av (65%) 287 (78%)
15_Av (73%) 297 (80%)
84_Av (99%) 300 (84%)
95_Av (74%) 324 (57%)
162 (99%) 325 (70%)
214 (78%) 330 (83,5%)
214a (69%) 333 (100%)
306 (82,5%) 348 (99%)
334 (88%) 350 (93%)
358 (100%) 356 (97%)
Confidence levels were calculated by the Pattern Expert Airspect program
after ANN and cross validation analysis with all HHT samples and all control
samples for spectral regions 3.150 - 2.750 cm-1 and 1.850 - 750 cm-1.
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cm-1 - 750 cm-1.
The Bhattacharyya coefficient in this application was
superior to t-test, entropy, roc or Wilcoxon (Mann-
Witney U test) feature ranking concerning misclassifica-
tion. Once the relevant features in order to differentiate
between HHT and non-HHT were defined, a 1-hidden
layer feed forward neural network with 3 hidden layer
neurons was trained 67 times using the spectral data of
the HHT and non-HHT samples. In each session the
neural network was trained with randomly selected 70%













Figure 3 Relevant wavenumbers/features used for ANN analysis of HH
Bhattacharyya coefficient was calculated. A wavenumber was selected if Bh
The selected wavenumber regions are marked by the black lined peaks anhalf of it, again randomly selected, was used for training
validation and the other half (test data, representing 15%
of the total) was used for testing the networks training
success. Only the test data were used to calculate the
performance. The validation data were used for early
stopping in order to avoid over training. This process
(training and testing) was repeated 67 times. As a conse-
quence, each observation (spectrum) was used in ten dif-
ferent test data sets (0.15 × 67 = 10.05). Because the test
data are not used in the training this provides a com-
pletely independent measure of the network accuracy.
In order to get a measure of the reliability the soft de-
cision network output is stored for each training session
and for each observation the mean and the standard de-
viation is calculated. By this, a classification was consid-
ered to be reliable if the distance between the mean and
the decision level 0.5 is greater the standard deviation.
All other observations were labelled as undefined. The
soft decision output of the NN is a number between 0
and 1. The soft decision output is a measure of the con-
fidence: 0.5 is interpreted as 50% confidence, 0 and 1 as
100% true negative or 100% true positive, respectively
(see Figure 4).
After 67 sessions of neural network training 6 samples,
out of 394, were reliably classified as false positive (trian-
gles in Figure 4) and 4 samples as false negative (circles
in Figure 4) (see Table 6). Their standard deviation (cal-
culated from at least 10 test data sets) did not reached
or crossed the decision point of 0.5 (50% confidence).
Based on our analysis criteria 21 samples (5%) could not
reliably be classified (see Table 6, undefined group).
Their standard deviation crossed the decision point as1100120013000




T patient and control group spectra. For each wave number the
attacharyya coefficient was greater than 5% of the greatest coefficient.
d open rectangles.
Figure 4 Confidence levels of ANN based classification. The measure of confidence of the ANN (soft decision output) is a number between 0
and 1. 0.5 is interpreted as 50% confidence, 0 and 1 as 100% true negative or 100% true positive, respectively. Based on the ANN soft decision
output the spectra are placed on the curve, corresponding to their confidence level. The term “Sorted Observations” refers to the number of
analysed spectra. Each observation represents one spectrum. False negative spectra are marked by a circle (with standard deviation, red line)
and the false positive spectra are marked by a triangle (with standard deviation, red line). The blue lines mark the undefined spectra whose
standard deviation crosses the 50% confidence decision boundary.
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sessions, typically 96% +/−1% of the test data were clas-
sified correctly with similar sensitivity and specificity.
But more importantly for future investigations, which
sample was wrongly classified differed considerably de-
pending on what data were selected for training and val-
idation. By excluding the undefined sample group we
calculated a sensitivity of 98% +/− 0.5% and a specificity
of 97% +/− 0.5%.
Intra and inter class Principal Component Analyses (PCA)
reveal overlapping and multi-modal clusters for the HHT-
negative and -positive groups
Based on the afore performed ANN analysis, about 5%
of the analysed spectra of the HHT group as well as the
control group could not reliably be classified and 4 true
HHT patients were misclassified. We wondered whether
there might be a higher degree of spectral overlap be-
tween the two groups and also a higher spectral intra
group heterogeneity as may be expected, i.e. that the
two groups do not fall into two well separated clusters
but overlapping clusters and that the clusters of each
group show a multi modal characteristic.
First, we performed an intra class principle component
analysis (PCA) in order to search for correlated observa-
tions within a class. For both spectral regions (region 1,
3150 cm-1 - 2750 cm-1; region 2, 1850 cm-1 - 750 cm-1)
we selected the four strongest eigenvectors for the
HHT-negative and HHT-positive groups (class) separatelyand projected the data onto the eight eigenvectors
resulting in 2×8 features (PC1-PC4 of the positive and
negative group and of region 1 and 2). The analysis re-
vealed that the spectral region 2 is more selective (better
cluster separation) than region 1 and both the HHT-
positive and HHT-negative class are multimodal (multiple
clusters) with an overlapping mode and in addition for
both classes some outliers were observed (Figure 5). This
confirms our hypothesis that there is to some degree an
intra class spectral heterogeneity.
Next, we did inter class PCA, i.e. we calculated the
common eigenvectors of the HTT-negative and HTT-
positive group and projected the data on these eigenvec-
tors. Again, the spectra for the HHT-positive and HHT-
negative group are multimodal with overlapping modes
and strong outliers can be observed (Figure 6). These re-
sults might explain why the ANN had problems to clas-
sify some spectra correctly. Future investigations need to
analyse whether these are regular biological variations or
influenced by other factors like sample transport, pro-
cessing or instrument dependent data recording.
Discussion
The goal of this study was to evaluate if Mid-IR spec-
troscopy can be used for the diagnosis of HHT. Here,
we have demonstrated now for the first time that the
IR-spectra of HHT patients show a disease-specific IR-
fingerprint and clearly differ from that of a healthy con-
trol group. Thus, IR-spectroscopy in combination with
Table 6 Summary of misclassified and undefined samples
after ANN analysis using 238 spectral features
Non-HHT
samples classified




























Figure 5 Intra class principle component analysis (PCA) for the HHT-n
for the HHT-negative (blue circles) and the HHT-positive (red crosses) grou
1850–750 cm-1. Projecting the data onto the eight eigenvectors, resulting i
region 1 and 2), shows that the HHT-positive and HHT-negative groups are
the two classes.
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ered to be a serious alternative diagnostic method com-
pared to clinical and genetically based methods.
This pilot study by using two different ANN analyses
yielded already a sensitivity and specificity of about 95%
to 98% depending on, which method, analysis step and
what data was used for the calculation. We are con-
vinced that improvements and changes in ANN analysis
parameters, increased sample numbers and sample prep-
aration/transport will most likely lead to a further in-
creased sensitivity and specificity. We have shown for
the ANN analysis with the Pattern Expert program that
concentrating on two or only one region can lead to
slightly different predictions. In addition, the ANN ana-
lysis was done with the software programs standard set-
tings. Our second ANN analysis approach has shown
that the number of features, the number of training ses-
sions and the selection of training and validation data
sets influence the ANN decision. Furthermore, over the
course of our study, we have seen that with increasing
numbers of patient samples the prediction accuracy of
the method improved. Future work has now to concen-
trate on the development of an improved algorithm by
modifying program parameters, settings and data pre-
processing.
It is important to note that the here presented method
of IR-spectroscopy is not measuring the change of a
single protein or biomarker but encompasses the overall
metabolic change caused by a disease, which is then mir-
rored by a specific IR-spectrum or biochemical fingerprintegative and HHT-positive group (class). The four best eigenvectors
p were seleted separately for region 1, 3150–2750 cm-1, and region 2,
n 2x8 features (PC1-PC4 of the positive and negative group and of
multimodal (multiple clusters) with an overlapping mode between
Figure 6 Inter class principle component analysis (PCA) between the HHT-negative and HHT-positive groups. The analysis was done for
region 1, 3150–2750 cm-1, and region 2, 1850–750 cm-1. The projection shows that the spectra for the HHT-positive group (red crosses) and
HHT-negative group (blue circles) are multimodal with overlapping modes and outliers.
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Figure 3. The identified wavenumbers for the feature se-
lection represent regions for biomolecules like proteins
(~1800 cm-1 – 1400 cm-1) and DNA/RNA (~1400 cm-1 –
1000 cm-1) in general with may be specific peaks for lipids
(~1750 cm-1), proteins secondary structure represented by
the Amide I and II bands at ~1650 cm-1 and ~1550 cm-1
and carbohydrates/glycogen (~1155 cm-1/~1030 cm-1)
[20]. The selected wavenumbers suggest that the majority
of metabolic changes in HHT patients affect the biomol-
ecule group of proteins.
It is possible that some patients, despite their disease
and may be independent of their disease status, still show
a metabolic “fingerprint” that is closer to the average
spectrum of healthy people than to the spectrum of HHT
patients and of course vice versa. As a simple example,
some patients might have regular and sometimes dramatic
episodes of nose bleeds but still normal hemoglobin
values. The more samples of patients and healthy people
are analysed by an ANN the more likely it is that the
ANN learns to classify these “outliers” to the correct
group. Therefore, we are convinced that more and more
samples will lead to a higher sensitivity and specificity of
this method. In line with this, our inter and intra class
PCA analyses with all spectra demonstrated that both
groups (classes), HHT and non-HHT, are not character-
ized by a single modality, but are multi modal. We would
hypothesize that the inter and intra class observed spectral
heterogeneity is more likely caused by a natural biological
and physiological variance. In regard of this, it is interest-
ing to note, that the spectra 214 and 214a represent the
same sample, measured at different times but with the
same result. This would suggest that instrument and
measurement conditions can most likely be excluded as a
factor for this false positive result.
Nevertheless, other factors like sample transport and
plasma preparation cannot be excluded and might playan additional role. For example, there was less spectral
heterogeneity among the blood donor group than the
HHT group. The blood donor samples were provided to
us by the blood donor centre as frozen plasma, prepared
after a standardized protocol, whereas the HHT EDTA-
blood samples were collected over a period of about 3
years and sent to us by regular postal mail. Once we re-
ceived the EDTA-blood, the plasma was instantly pre-
pared and stored away at −20°C. In general, transport
time was one to two days by regular mail. However, we
do not know how much time passed until the blood was
sent to us and to what temperatures the blood was ex-
posed to during transport. Interesting enough, two out
of three samples from Spain, samples 356 (ENG muta-
tion) and 358 (non-HHT control), that were sent to us
by postal mail and took three days, were misclassified.
But it is also possible that the samples were mislabelled.
Then, the prediction would be correct. A sample from a
healthy non-HHT person, sample 214, took several days
before it reached us and was classified to belong to the
HHT group. When we asked for a second probe about a
year later this sample was correctly classified healthy.
We wanted to keep the shipping for this study as simple
as possible and overall our data show that this is a feasible
way. However, for future studies it should be considered
to process the blood as soon as possible. Furthermore, we
recommend that once a person is classified to have HHT a
second sample is ordered and measured. We had one case,
sample 306, classified to have HHT but by sequencing we
excluded the family specific mutation. When we analysed
a second sample about a year later, this time the person
was correctly classified to belong to the healthy group.
What might have caused the first false prediction could
have been a prolonged episode of a slipped disc at that
time leading to inflammation like responses as the patient’s
blood count suggests. It is well known that inflam-
mation, especially for chronic inflammatory disorders,
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[21,22]. One of many features of these is an increased
expression of the angiogenesis factor VEGF, which is
also reported for HHT patients [23,24].
Other samples might be misclassified because the pa-
tients do not just have HHT but other diseases. For ex-
ample, sample 325, which was classified into the false
negative/undefined group, is a JP-HHT patient with a
SMAD4 mutation. Obviously the patient’s spectral pat-
tern does not exactly fit the HHT spectrum. By analysing
a sufficient amount of JP-HHT patients it might be pos-
sible to differentiate between HHT and JP-HHT patients.
Furthermore, other diseases may have symptoms that
can cause an HHT-like IR-fingerprint. Such a case might
be 334, the son of a genetically confirmed HHT mother,
who was classified into the false positive or undefined
group. By DNA sequencing, we excluded for the son the
family specific mutation. However, on his questionnaire
he stated to have an HAVM but otherwise no other
HHT-typical symptoms. One proband, 162, the daughter
of an HHT mother, was considered to have no HHT,
based on her questionnaire, but her sample was consist-
ently classified into the false positive group. She might
be one of the rare cases that still do not show any symp-
toms at an age of 65 but her IR spectrum suggests that
she might have HHT. For all the false positive, false
negative and undefined cases it would be of course desir-
able to get a fresh sample for a second analysis.
By using IR-spectroscopy as a diagnostic tool, we do
not think that IR spectra from other diseases will signifi-
cantly compromise the HHT-specific IR-fingerprint lead-
ing to a high number of false positive classifications. For
this purpose, the average spectrum of the HHT group
was compared to a group of 99 prostate cancer samples
and a group of 432 bronchial carcinoma samples. As a
result, the HHT spectra were clearly differentiated from
the prostate cancer and bronchial carcinoma spectra
(data not shown). In addition, we tested whether gender
might influence the analysis. There was no difference be-
tween female and male spectra. We also tried to differ-
entiate between endoglin and ALK1 mutation carriers
but no spectral difference was observed between these
two groups.
Aside of demonstrating that IR-spectroscopy is a
promising diagnostic method, we can also present sev-
eral new endoglin and ALK1 mutations due to the infor-
mation the patients provided from the questionnaires.
Based on this, 16 german patients reported 11 different
endoglin mutations, 29 german patients reported 22 dif-
ferent ALK1 mutations and 2 german patients a SMAD4
mutation. Previous mutation analyses for german HHT
patients have shown that the endoglin ALK1 mutation
ratio in Germany is slightly shifted towards ALK1
[25,26]. Our data do not only confirm this observationbut suggest that ALK1 mutations are far more frequent
in the german HHT population than endoglin mutations
as it is also the case for the European-Mediterranean
population.
Conclusion
With the here used methods, HHT can be diagnosed by
Mid-IR-spectroscopy in combination with ANN analysis
with a sensitivity and specificity of at least 95%. Future
work needs to concentrate on the aspects of sample
transport and processing and increasing sample numbers
to help to improve ANN analysis. Furthermore, in the
current study most of the analysed probands showed
typical HHT symptoms, with a few exceptions. There-
fore, the question is, can we diagnose HHT by IR-
spectroscopy at an early stage or young age when HHT
symptoms are not yet present, easily missed or
misinterpreted. Some of our results might suggest that
this is possible. In order to answer this question, yet
symptom-less members of HHT families need to be
screened by IR-spectroscopy in combination with a gen-
etic profiling for endoglin, ALK1 and SMAD4 mutations.
An initially expensive investigation, but worthwhile for pa-
tient monitoring and surveillance that in addition might
help to reduce costs for our health systems. The advantage
of IR-spectroscopy in combination with ANN analysis is,
once a disease-specific algorithm is established, no
recalibration of the system is required. In addition, each
new sample can be used to further train the ANN for an
even more disease-specific algorithm. Further advantages
are first, only minimal amounts of just 1 μl plasma are re-
quired. Second, measurement times are fast, less than one
minute. Third, diagnosis is not based on interpretation of
may be uncertain clinical data. And last but not least, the
method is inexpensive.
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